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The natural history and pathogenic potential of the recently identified TT virus (TTV) are currently a matter
of intensive investigation. In an attempt to shed some light on these issues, nasal and blood specimens of 1-
to 24-month-old children hospitalized with a clinical diagnosis of acute respiratory disease (ARD) were
examined for the presence, load, and genetic characteristics of TTV. The results have indicated that at least in
young children, the respiratory tract not only represents a route by which abundant TTV can be shed into the
environment but also may be a site of primary infection and continual replication. Although we found no
compelling evidence that TTV was the direct cause of ARD in some of the children studied, the average loads
of TTV were considerably higher in patients with bronchopneumonia (BP) than in those with milder ARD,
raising interesting questions about the pathophysiological significance of TTV at this site. Furthermore, group
4 TTV was detected almost exclusively in children with BP.
TT virus (TTV)—a small, nonenveloped virus with a single-
stranded, negative-polarity, circular DNA genome of 3.8 kb—
was initially thought to be a circovirus similar to chicken ane-
mia virus, porcine circovirus, and other viruses of animals, but
it is now under consideration as the possible type species of an
independent virus family (17, 18, 34, 35). The taxonomy of the
vast array of related viral agents that have been identified in
humans since the first description of TTV by Nishizawa et al.
in 1997 (21) is also uncertain. Recently, however, Okamoto
and Mayumi (22) have divided TTV isolates into at least four
phylogenetic clusters differing by over 40% at the nucleotide
level: group 1 has the original TTV isolate as the prototype and
includes genotypes 1 to 6; group 2 has PMV as the prototype
and comprises genotypes 7, 8, 17, 22, and 23; group 3 has
SANBAN and SENV as representative isolates and includes
genotypes 9 to 16 and 18 to 20; and group 4 has YONBAN as
the prototype and includes genotype 21. Furthermore, while
the present report was in preparation, the same group identi-
fied several novel genotypes within group 4 TTV as well as
members of a proposed fifth group (26). Additional related
viruses are more dissimilar due to their smaller genome (2.8
kb) and are presently designated TTV-like minivirus or TLMV
(6, 33, 34).
The natural history and pathogenic potential of TTV are
currently the subject of active investigation. From the epide-
miological standpoint, evidence has accumulated that TTV
viremia is extremely common in the general population world-
wide, starting from early childhood (1, 5, 10, 26, 27), implying
the existence of a very efficient means of transmission, and the
observation that infectious TTV is shed in the feces has led to
the suggestion that the fecal-oral route is the most likely one
(36). With regard to the life cycle in infected hosts, both self-
limited and persistent systemic TTV infections have been de-
scribed (reviewed in reference 5) and chronic TTV viremia has
been shown to result from the production and clearance of
1010 to 1011 virions per day (16), indicative of the existence of
body sites where the virus is continuously and actively repli-
cated. Furthermore, it has been reported that chronically in-
fected individuals harbor high levels of mature TTV DNA as
well as replicative DNA intermediates and mRNA in all body
sites examined (23) except the central nervous system (14),
thus implying that TTV is polytropic in nature or grows in a cell
type(s) that is represented throughout the human body. With
regard to pathogenesis, early indications that TTV might cause
some forms of cryptogenetic hepatitis have been questioned (7,
20) while attempts to link the virus to other diseases have
either been unsuccessful or need confirmation (5, 38), leaving
the virus with “orphan” status with regard to clinical disease.
Thus far, the routes of TTV entry into the body, the loca-
tions of initial virus amplification before infection becomes
systemic, and the clinical consequences of primary infection, if
any, have been investigated only to a limited extent. In this
study we have approached these issues by examining children
with acute respiratory infections (ARD). The results have in-
dicated that the respiratory tract represents not only a route by
which abundant TTV can be shed into the environment but
also a site of primary infection and continual replication. Al-
though we found no compelling evidence that TTV was the
direct cause of ARD in some of the children studied, average
burdens of TTV were considerably higher in patients with
bronchopneumonia (BP) than in those with milder forms of
ARD, raising interesting questions about the pathophysiolog-
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ical significance of this virus. Furthermore, group 4 TTV was
detected almost exclusively in children with BP.
MATERIALS AND METHODS
Study subjects, specimens and detection of CRV. All specimens were from
children with ARD admitted to the Department of Pediatrics, University Hos-
pital of Pisa, and were collected on admission day after informed parental
consent had been obtained. The duration of clinical symptoms before hospital-
ization was 6.8  5.3 days. Nasal samples were harvested with sterile alginate
swabs that were gently pushed toward the nasopharynx until resistance was
encountered and then rotated a few times to collect abundant fluid and cells.
Plasma was obtained by centrifuging blood collected under nuclease-free condi-
tions in sodium citrate tubes. Peripheral blood mononuclear cells (PBMC) were
obtained by standard Ficoll-Hypaque density gradient centrifugation (ICN Bio-
medicals, Aurora, Ohio), washed thoroughly, and treated to remove adsorbed
extracellular virus as previously described (15). Simultaneous nasal and plasma
samples from the 24 children who entered the pilot study (19 boys and 5 girls
aged 1 to 24 months [mean, 9.5 months], all negative for hepatitis B virus,
hepatitis C virus, and human immunodeficiency virus; no history of blood trans-
fusions or blood product use) were harvested from November 1999 through April
2000. The nasal secretions collected from these children were quantified by
weighing the swabs before and after collection (range of weights, 13 to 72 mg;
mean  standard deviation, 42  15 mg), diluted 1:10 (wt/vol) with phosphate-
buffered saline (PBS), and clarified at 900  g at 4°C for 10 min to separate cells
and cell debris. Finally the cell-free nasal fluid was stored in aliquots at 20°C
until used for DNA extraction. The cell pellets, whose contribution to the total
weight of secretions was found to be negligible, were repeatedly washed in
abundant PBS, resuspended in 200 l of PBS, and also stored at 20°C with no
examination of their cellular composition. The samples used to expand the
population investigated were also from children aged 1 to 24 months and were
submitted to our laboratory for routine virological analysis between May 2000
and November 2001. Some swabs from this second group were vortexed in 0.5 ml
of sterile saline, and the resulting suspension was stored as above, without further
processing. All nasal samples were tested for common respiratory viruses (CRV)
by direct immunofluorescence (adenovirus, cytomegalovirus, influenza A and B
viruses parainfluenza virus types 1 to 3, and respiratory syncytial virus [RSV]),
enzyme immunoassay (RSV), and rapid culture in shell vials (all the above
viruses).
TTV detection and quantification. DNA was extracted from 200-l samples of
all specimens by using the QIAamp DNA minikit (Qiagen, Chatsworth, Calif.) as
specified by the manufacturer. The presence and load of TTV in nasal and
plasma specimens were determined in a single step by a previously described
TaqMan (TM)-PCR assay (14, 27). This assay is based on a highly conserved
segment of the viral untranslated region (Table 1) and has the potential for
sensitive and specific detection of all the genotypes of TTV present in GenBank
at the time of writing. Furthermore, the method does not detect TLMV, as
determined by testing TLMV plasmid sequences and also confirmed by the
sequence data below. The procedures used for quantification of copy numbers
and evaluation of specificity, sensitivity, intra- and interassay precision, and
reproducibility have been described previously (27). The lower limit of sensitivity
was 1.0  103 viral genomes per ml or g of total DNA for both nasal and blood
specimens. The presence of PCR inhibitors in extracted nasal secretions was
ruled out by testing several nasal samples spiked with known numbers of TTV
DNA copies. The yields of total DNA extracted from PBMC and nasal cells were
determined by agarose gel electrophoresis and by comparison with appropriate
dilutions of quantitative molecular markers.
TTV typing by group-specific PCR assays. Selected specimens found positive
by the TM-PCR assay were amplified by four nested or seminested PCR proto-
cols, using the group-specific primers listed in Table 1. The reactions were
performed in a Perkin-Elmer 9600 thermal cycler (Applied Biosystems, Foster
City, Calif.), amplified products were analyzed by gel electrophoresis followed by
ethidium bromide staining, and the amplicon size was determined by comparison
with appropriate molecular size markers. To exclude the presence of carryover
contamination, each round of assays included appropriate negative controls
added during the steps of DNA extraction and PCR amplification. Specimens
were examined at least in duplicate, and if the results of tests of different
specimens from a patient differed, the specimens were reextracted and tested
again in duplicate. The sensitivity of each group-specific assay was measured by
testing serial dilutions of a known concentration of recombinant plasmids having
the appropriate segment of viral genome inserted and found to range between 10
and 100 DNA copies.
TABLE 1. PCR oligonucleotides used for quantifying and grouping TTV isolates
Oligonucleotide Sequence (5-3)a Genomelocalization
Position
(nt)b
PCR product
length (bp)
Universal TM-PCR 63
AMTS GTGCCGIAGGTGAGTTTA UTR 177–194
AMTAS AGCCCGGCCAGTCC UTR 226–239
AMTPTUc TCAAGGGGCAATTCGGGCT UTR 205–223
Group-specific PCR
Group 1 191
TTV2 CAGTTAGTGGTGAGCCGAA ORF1 1348–1366
TTV3 GACACAGAIATTACAGCCCC ORF1 1126–1145
TTV5 ACAGCCCCCAGCATACATCC ORF1 1138–1157
TTV6 GTGGTGGCATAGACCGTTAG ORF1 1309–1328
Group 2 259
PMV1 ACAIAGATGTCCCTGGAGTAGA ORF1 1018–1039
PMV2 AGAGGCACTGATGTTTACTGGC ORF1 1327–1348
PMV3 TGGAGTAGATCGAACGAAGA ORF1 1031–1050
PMV4 CTGTAAATAGAGTGGGGGG ORF1 1271–1289
Group 3 255
SS1 GACCARCTAGACCTGGCCAGATA ORF1 1061–1083
SS2 GTTTGTGGTGAGCMGAAYGG ORF1 1382–1401
SS4 GTACCASTKGTCTWCAAA ORF1 1298–1315
Group 4 273
PY1 CCATTTTGTRCAGCCCGCCA UTR 103–122
PY2 ACGGCATGACTTTGTGTYCTG UTR 389–409
PY3 AGCCCGCCAATTTCTGTTC UTR 114–132
PY4 GGAGAACAGAGCRRGGGAAT UTR 367–386
a I, inosine; R, A or G; M, A or C; Y, C or T; S, G or C; K, G or T; W, A or T.
b Nucleotide (nt) positions are according to isolate AB017610 for TM-PCR and group 1-specific PCR and to isolates AF261761, AB028669, and AB038624 for group
2-, 3-, and 4-specific PCR, respectively.
c AMTPTU probe was labeled with 6-carboxyfluorescein and 6-carboxytetramethylrhodamine at the 5 and 3 ends, respectively, and contained a propynilic chemical
group bound to each thymidine.
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Sequencing and sequence analysis. Amplification products from the group-
specific PCR assays were directly sequenced using the Big Dye Terminator
cycle-sequencing kit (Applied Biosystems). Cycle sequencing was carried out
with an automatic DNA sequencer (ABI model 373; Applied Biosystems) and
performed in both orientations for confirmation. Nucleotide sequences were
aligned with previously published sequences. Multiple alignments were created
using CLUSTALW, and phylogenetic relationships were estimated by using
DAMBE (version 4.0.59 [37]) and the neighbor-joining method.
Statistical analysis. Pearson’s chi-square test was applied to evaluate the
heterogeneity of contingency tables. Differences between means and distribu-
tions were evaluated by the two-tailed Student t test and the Wilcoxon rank sum
test, respectively. Associations between variables were determined by applying
Pearson’s correlation coefficient.
Nucleotide sequence accession numbers. Sequences obtained were submitted
to GenBank (accession no. AY093391 to AY093412).
RESULTS
In-depth examination of TTV in 24 paired nasal and blood
specimens. For the pilot study of the nasal and blood speci-
mens, nasal swabs were weighed before and after specimen
collection to permit precise comparisons of viral load with
those in plasma, and nasal fluids and cells in the swabs were
processed separately and invariably tested in parallel with the
corresponding plasma and PBMC. Universal TM-PCR analysis
detected TTV in 18 of the 24 children studied, and in each case
all specimens were concordantly positive or negative. As shown
in Fig. 1, the levels of TTV found in individual patients varied
widely but the loads in the four specimens from each patient
were clearly correlated. Importantly, TTV DNA copy numbers
per milliliter in nasal fluids constantly exceed those in the
corresponding plasma samples, in 15 cases by over 1 log10 unit
and in one by as many as 5 log10 units (mean difference, 2 log10
units; P  0.001). TTV DNA copy numbers per microgram of
total DNA associated with nasal cells were also often but not
constantly greater than in the corresponding PBMC, and the
differences were less pronounced (mean difference, 0.5 log10
unit, P  0.02).
The 18 pairs of nasal fluid and plasma TTV isolates were
then characterized by grouping and sequencing. Groups were
determined by reamplifying the clinical specimens with four
specifically designed group-specific PCR assays targeted either
to the viral ORF1 (groups 1 to 3) or UTR (group 4). Of the
nasal specimens, two were not amplified by any such reaction
and remained unclassified although they again reacted TTV
positive when retested by universal TM-PCR. The others
yielded either one (11 specimens), two (3 specimens), or three
(2 specimens) positive reactions, indicating that the respiratory
tracts of five children contained more than one TTV group.
Group 3 was the most heavily represented (14 samples), fol-
lowed by groups 1 (6 samples) and 4 (3 samples). Character-
ization of plasma TTV yielded results identical to those for the
nasal fluid TTV in 13 cases. The others showed different forms
of discordance, which were also demonstrated by the results of
examining the corresponding PBMC and nasal cells, although
the presence of an unclassified TTV in one of the two sites was
common (Table 2).
Amplicons from 32 of 45 group-specific PCR assays were
sequenced, and in each case the original classification by the
PCR assay was confirmed by sequence analysis (data not
shown). Twenty-seven sequences were in the ORF1 region and
could be used for a meaningful comparison of paired nasal and
plasma sequences as well as for classification of the viral iso-
lates into genotypes. Of 12 paired nucleotide sequences exam-
ined, 6 were identical; the others diverged between 1 and 16%.
Figure 2 shows the phylogenetic trees constructed by using
such sequences together with representative GenBank se-
quences. Group 1 sequences (interpatient nucleotide homolo-
gies between 55 and 97%) clustered within genotypes 3 (five
sequences), 1 (two sequences), and 6 (one sequence). Group 3
sequences (interpatient nucleotide homologies between 54 and
99%) fell into genotypes 11 (eight sequences), 20 (two se-
quences), 15 (two sequences), and 16 (one sequence). The
additional five amplicons sequenced, being derived from group
4-specific PCR assays, were less informative due to high con-
servation of the untranslated region targeted and showed a
maximum interpatient divergence of 3% (data not shown).
Correlation between TTV loads and ARD severity in a large
group of children. The above study had shown a tendency for
children with BP to have especially high titers of TTV (data not
shown). To further investigate this finding, we measured the
loads of TTV in additional pediatric specimens sent to our
laboratory for routine virological analysis. Thus, the eventual
total number of specimens examined was 100 nasal swabs and
151 plasma samples from a total of 157 hospitalized children.
A total of 54 nasal swabs and 62 plasma samples were from
FIG. 1. TTV loads in paired nasal and blood samples from the 18
children in the pilot study that were found virus positive in both
specimens. F, TTV DNA copy numbers in nasal fluid versus plasma;
E, TTV DNA copy numbers in total DNA from nasal cells versus
PBMC. Broken lines connect the data for each individual patient.
Most points lie above the diagonal line, indicating higher loads in nasal
samples than in blood samples.
TABLE 2. Discrepant results obtained by grouping
contemporaneous TTV-positive nasal and blood samples
Patient Sex
a/age
(mo)
Clinical
diagnosis
Group of TTV in:
Nasal
fluid
Nasal
cells Plasma PBMC
576 M/16 BP 3, 4 3, 4 3 3
4999 F/8 Bronchiolitis 3 3 NTb NT
5174 M/5 Bronchiolitis 3 3 1, 3 1, 3
5210 F/10 BP 3 3 NT NT
5575 M/9 BP NT NT 1 NT
a M, male; F, female.
b NT, not typeable.
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children with X-ray-confirmed BP. The others were from chil-
dren with laryngitis (10 cases), bronchitis (18 cases), or bron-
chiolitis (65 cases), after checking that they showed no signif-
icant differences in TTV detection rates and load distributions,
we treated them as a single category. As shown in Table 3 and
Fig. 3A, TTV was detected more frequently and at higher titers
in BP patients than in other ARD patients, regardless of
whether the test was conducted on nasal or plasma samples.
Furthermore, stratification by TTV load size showed that nasal
swabs with TTV values of 	9 log10 units per ml were almost
FIG. 2. Phylogenetic analysis of 27 TTV isolates from the pilot study. (A) Tree based on the 151-bp ORF1 segment amplified by the group
1-specific PCR. (B) Tree based on the 214-bp ORF1 segment amplified by the group 3-specific PCR. Both segments had primer nucleotides
subtracted. Nasal () and plasma (F) isolates from the present study are in boldface type. GenBank sequences are indicated by the isolate name.
The PMV isolate was used as the outgroup. Bootstrap values above 67% of 1,000 replicates are shown at branch points, to show the significance
of the grouping. Bars represent the number of nucleotide substitutions per site. Bars with numbers to the right of each tree indicate the TTV
genotypes within which the sequences identified in this study clustered (the others are omitted for simplicity).
TABLE 3. Detection and loads of TTV DNA in 100 nasal and 151 plasma samples, grouped by clinical diagnosis and CRV detection
Clinical diagnosis
and CRVb
detection
Nasal swab Plasma
No.
examined
No. (%)
positive
Mean TTV
load  SD
(log10 copies/ml)
a
No.
examined
No. (%)
positive
Mean TTV
load  SD
(log10 copies/ml)
BP
CRV 14 14 (100) 10.2  1.2 19 17 (89) 8.0  1.0
P  0.0053
CRV 40 39 (97) 8.9  1.7 43 40 (93) 7.5  1.4
Total 54 53 (98) 9.2  1.7 62 57 (92) 7.7  1.3
Other ARD P  0.0003 P  0.0001 P  0.028 P  0.003
CRV 22 14 (64) 7.8  1.9 50 41 (82) 6.7  1.5
CRV 24 20 (83) 7.5  1.4 39 29 (74) 6.9  1.2
Total 46 34 (74) 7.6  1.6 89 70 (79) 6.8  1.4
a TTV-positive samples only.
b CRV include adenovirus group, cytomegalovirus, influenza A and B viruses, parainfluenza virus types 1 to 3, and RSV.





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sixfold more likely to originate from children with BP than
were the ones with lower loads. Plasma load differences were
much less informative about this finding (Fig. 3B). Also, nasal
and plasma loads were again found to correlate (r  0.87,
corroborating what was observed in the pilot study. Of note,
the mean ages of patients with BP or other ARD were not
statistically different (12.8  7.9 and 9.8  6.8 months, respec-
tively). No correlation was observed between the age of the
children and TTV loads in nasal swabs (r  0.33) or plasma
(r  0.25). However, the viremia rate was 63% in 26 subjects
younger than 4 months and 95% in 42 subjects aged 12 months
or more, thus comparing well with previous findings (26).
Samples were also grouped according to whether the donors
had been found positive or negative for CRV by routine viro-
logical analysis. The only significant difference detected was
that the 14 CRV-positive BP patients had higher mean nasal
TTV loads than did the 40 CRV-negative BP patients (Table
2), regardless of whether they harbored RSV (9 children) or
other viruses (5 children).
Prevalence of group 4 TTV in patients with BP. In the pilot
study, the TTV groups were distributed uniformly regardless of
clinical diagnosis, except for group 4 TTV which had been
found only in four subjects with BP, raising the possibility that
this group was especially closely associated with BP. To further
investigate this aspect, we used the group 4-specific PCR assay
to examine 42 of the 53 TTV-positive nasal swabs from chil-
FIG. 3. TTV loads in the 151 plasma and 100 nasal fluid specimens from children with ARD, subdivided by respiratory disease (BP versus other
ARD). (A) Thick and thin lines represent nasal fluid and plasma samples, respectively. Most steps represent single patients. TTV loads in nasal
fluid and plasma differed significantly between patients with BP and other ARD at P  0.00001 and at P  0.00001, respectively (Wilcoxon test).
(B) Results stratified based on the TTV load in plasma (dotted line) and nasal fluid (continuous line). Each point represents the ratio between
the number of patients with BP and the number of patients with other ARD. The numbers in parentheses are the number of patients with BP/the
number of patients with other ARD.
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dren with BP and 31 of the 34 TTV-positive nasal swabs from
children with ARD. We found that 9 (21%) and 1 (3%) of
specimens, respectively, reacted positively (P  0.03). Of the
10 patients with group 4-positive nasal swabs, 6 also yielded the
same TTV group in plasma.
Longitudinal study of two children initially TTV positive in
the respiratory tract and negative in plasma. In the cross-
sectional study above, we had examined contemporaneous na-
sal and plasma samples from 94 patients. Of these patients, six
had tested positive only for the nasal sample, thus indicating
that they were experiencing a respiratory TTV infection in the
absence of, or prior to, systemic TTV involvement. For two of
these patients we could examine additional samples obtained
at later times. Patient 3936 was 3 months old when first tested,
and because he had obstructive BP with recurring clinical
symptoms and was persistently negative for CRV, he was ex-
amined several times over 16 months. As shown in Table 4, the
nasal cavity of this child was already TTV positive when he was
first examined at 3.5 months of age, and it remained constantly
positive with titers that increased steadily during the first 2.5
months of observation. On the other hand, the child’s blood
tested TTV negative three times before becoming positive at
age 4.5 months; it subsequently remained positive with titers
that also rose gradually but to a lower plateau than in the
respective nasal samples. Nasal and plasma TTV sequences
from this child were of group 1 and were identical at all times,
but they could not be assigned with certainly to any currently
known genotype (77 and 65% nucleotide homology to geno-
types 6 and 4, respectively). For the second patient, a 3-month-
old baby with laryngitis, we could examine only one additional
plasma sample obtained 2 weeks after TTV had been detected
in the nose but not in the plasma. At the second sampling, the
plasma had converted from negative to positive (4.4  106
TTV DNA copies per ml). Thus, in both these patients, TTV
infection of the respiratory tract had clearly preceded systemic
infection.
DISCUSSION
The amazingly high prevalence of chronic TTV infections in
healthy individuals worldwide represents a serious hurdle to
the elucidation of their natural histories and clinical signifi-
cances. Reported detection rates of viremia in the general
population have varied considerably depending on the breadth
and sensitivity of the diagnostic PCR assays used, but whenever
these were adequate, the detection rates easily ranged over
80% (reviewed in reference 5). Additional obstacles are the
extraordinary genetic heterogeneity of TTV (discussed in the
introduction); the high frequency of mixed infections by mul-
tiple TTV genotypes (up to 90% in certain studies [29]), which
presumably reflects a lack of cross-immunity; and the large
variations in viral loads found in individual subjects (from 103
to 108 DNA copies per ml of adult plasma in our hands [27]).
The present investigation of TTV in juvenile patients with
ARD consisted of two parts. The first was an in-depth study of
24 subjects in whom most of the above variables were taken
into account, while the second enrolled a larger number of
diseased children to focus on aspects that had appeared to
merit a more extensive evaluation. Collectively, the results
have confirmed the widespread diffusion and early acquisition
of systemic TTV infection by showing that 84% of 151 children
aged 1 to 24 months had the virus in their plasma. This prev-
alence is comparable to what was previously observed in
healthy adults living in the same area as the study children (27)
and in other geographical regions (25). According to available
data, early TTV infection can be the result of transplacental
transmission (11, 30) as well as of intra- or extrafamilial post-
natal exposure to the virus (31).
The results have also shown that 87% of 100 children exam-
ined harbored TTV in the upper respiratory tract. Because
nasal viral loads were often quite high, this indicates that at
least in young children the respiratory tract may represent an
important route of TTV excretion. Together with evidence
discussed below, this suggests that respiratory transmission of
TTV might be very significant and might make a greater con-
tribution to the widespread diffusion of this virus than other
proposed postnatal forms of transmission, including the fecal-
oral route. In this regard, it is important to note that all spec-
imens examined in the present study were collected at the time
of hospital admission, thus excluding recent nosocomial acqui-
sition of the observed TTV infections. Incidentally, the 24
children in the pilot study were also tested for TLMV; speci-
mens from 23 were positive in plasma and specimens from 22
were positive in the respiratory tract (data not shown), thus
suggesting that TTV and TLMV may share important epide-
miological features.
Genetic characterization of TTV was limited to the children
in the pilot study; nevertheless, it revealed a large heterogene-
ity, as shown by the detection of at least three groups and eight
genotypes of the virus. That we detected no group 2 TTV
sequences might reflect a relative infrequency of this group
worldwide (12). It should also be noted that we made no
attempt to further type, by sequence analysis or otherwise, the
isolates that were not classified by the four group-specific PCR
assays used; they may have belonged to the several genotypes
of groups 4 and 5 described after such assays were designed
(26) or to hitherto unrecognized genetic forms of TTV. As
pointed out by Okamoto et al. (23), the extent of TTV diversity
currently recognized is already unusually great for a DNA virus
but is bound to increase substantially with the accumulation of
sequence data worldwide. Importantly, detection of mixed
TABLE 4. Time course of detection of nasal and
blood TTV loads in child 3936
Age (mo.)
TTV DNA load
(log10 copies/ml or g of total DNA)
Nasal fluid Nasal cells Plasma PBMC
3 Nega
3.5 6.25b Neg
4 Neg
4.5 7.5 5.2 5.1 3.9
5 7.3 7.1
6 10.8 9.4 8.1 8.7
8 10.0 9.2 8.5 8.2
9 9.4 7.8 7.6 7.9
10 9.7 9.5 8.8 9.4
12 11.4 9.5 9.0 6.9
14 9.6 7.4 8.0 7.1
16 10.4 8.1 8.0 7.4
a Neg, 1.0  103 log10 copies per ml.
b TTV load measured in unseparated nasal fluid and cells.
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populations of TTV belonging to more than one group (up to
three groups) in a single subject was a frequent finding of this
and previous studies (3, 9, 19, 28) and represents a further
indication of the ubiquity and heterogeneity of TTV infection.
Recent data have shown that adults can harbor different mix-
tures of TTV genotypes in different organs, suggestive of a
preferential tropism of certain TTV strains for specific tissues
(8, 23, 24). However, we found no evidence in the present
study for the existence of genotypes exclusively tropic for the
respiratory tract.
Too few cells could be retrieved from our nasal swabs for a
reliable search of viral DNA intermediates or mRNA that
might unequivocally demonstrate ongoing local TTV replica-
tion. However, overall data provided convincing evidence that
at least part of the TTV present in the respiratory tract was
produced locally. (i) As mentioned above, nasal TTV loads
were often extremely high; (ii) in the children for whom a
precise comparison of nasal fluid and plasma loads was possi-
ble, the former specimen constantly exhibited higher TTV copy
numbers per ml than did the latter; (iii) thoroughly washed
cells retrieved from nasal swabs were uniformly TTV positive
and often contained more viral DNA copies per microgram of
total DNA than did the corresponding PBMC; (iv) in some
children, nasal and blood TTV were genetically discordant, as
if they were partly or totally derived from independent infec-
tions (23); and, lastly but most importantly, (v) some children
harbored TTV in the nose but not in plasma while the opposite
situation was never observed when virus detection was per-
formed by universal TM-PCR analysis. Coupled with findings
revealing the presence of molecular markers of TTV replica-
tion in the lungs (4, 23, 32), these data leave little doubt that
the respiratory tract is a site of continual TTV replication.
Furthermore, examination of serial samples from two children
demonstrated quite clearly that TTV infection of the respira-
tory tract can precede systemic infection, thus suggesting that
the respiratory tract can also be a port of entry and a place of
primary infection for TTV. This study was conducted with
hospitalized children who had developed respiratory symptoms
several days earlier. Examination of specimens collected ear-
lier after clinical presentation should facilitate detection of
primary respiratory TTV infections.
Ethical reasons did not permit the collection of suitable
nasal samples from healthy children, thus preventing an eval-
uation of whether the underlying ARD could explain the high
TTV prevalence rates and loads observed in the study patients.
However, the data revealed an interesting correlation between
TTV infection and clinical status. In fact, TTV prevalence and
loads in both nasal swabs and plasma were significantly higher
in patients with BP than in those with milder disease. The
significance of such finding remains elusive; however, if TTV
were directly involved in BP etiology, one would have expected
that BP patients who tested negative for CRV would be more
frequently TTV infected or would have higher TTV burdens
than the CRV positive ones. Because, in contrast, the mean
TTV loads were higher in CRV-positive BP patients, it seems
more plausible that TTV infection may augment the severity of
disease induced by other agents. Such a mechanism would be
reminiscent of the pathogenic features of several related vi-
ruses of animals, including chicken anemia virus, porcine cir-
covirus type 2, and beak and feather disease virus of parrots,
which are known to augment the severity of concomitant bac-
terial and viral infections, presumably due to the ability to
replicate in proliferating lymphocytes and to impair the anti-
microbial defenses of the host (2, 13). Importantly, TTV has
also been shown to replicate in stimulated PBMC (15). Also,
because it is likely that TTV replicates solely or most effectively
in the presence of active cell DNA synthesis (5), it is plausible
that, as with other single-stranded DNA viruses, TTV replica-
tion in the respiratory tract is boosted by concomitant local
infections by other agents, due to stimulation of resident lym-
phoid cells, influx of activated leukocytes, or ongoing regener-
ation of damaged tissue.
Another intriguing finding of the present study is that group
4 TTV was detected almost exclusively in children with BP,
raising the possibility that this group is especially closely asso-
ciated with severe ARD. That in several such cases group 4
TTV was detected in nasal swabs but not in plasma is indicative
of an ongoing primary infection or superinfection in the respi-
ratory tract and is therefore in line with this possibility. It
should, however, be noted that our group 4-specific PCR assay
had a restricted range of detection, since it was designed when
the only group 4 sequences in GenBank were of genotype 21,
while additional genotypes in this group have been identified
by Peng et al. in a more recent investigation of Japanese and
Chinese children (26). This, possibly in combination with geo-
graphical differences in the distribution of TTV genotypes,
may explain the lower rate of group 4 TTV detection in the
present study relative to what was observed by Peng et al. (26)
and points directly to genotype 21 for a possible association
with BP. Indeed, there are many examples of viral infections
(papillomaviruses, adenoviruses, enteroviruses, etc.) that have
different pathological consequences depending on the geno-
type of the virus involved. Further studies are clearly war-
ranted.
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